Also trades as: NEU.AX (ASX) · $vol 8M
NURPF OTC
Neuren Pharmaceuticals Limited
1W: +2.4%
1M: -12.1%
3M: +19.0%
YTD: +10.6%
1Y: +19.0%
3Y: +62.8%
5Y: +1313.9%
$14.28
+0.34 (+2.42%)
Weekly Expected Move ±6.0%
$13
$13
$14
$15
$16
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$125M
+1212.4% ▲
Capital Expenditures
$37K
-269.9% ▼
5Y CAGR: +43.9%
Free Cash Flow
$125M
+1211.1% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$40M
-279.4% ▼
Net Change in Cash
$1M
+109.3% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$8M | $184K | $157M | $142M | $30M |
| Depreciation & Amort. | $8K | $10K | $17K | $0 | $23K |
| Stock-Based Comp. | $840K | $2M | $0 | $0 | $0 |
| Change in Working Capital | -$3M | $533K | $23M | -$158M | $96M |
| Other Non-Cash Items | $3M | $2M | $8M | $4M | -$1M |
| Operating Cash Flow | -$10M | $4M | $185M | -$11M | $125M |
| — Investing Activities — | |||||
| Capital Expenditures | -$10K | -$19K | -$40K | -$10K | -$37K |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | -$211M | $0 | -$88M |
| Investment Sales | $0 | $0 | $0 | $4M | $0 |
| Other Investing | $0 | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$10K | -$19K | -$211M | $4M | -$88M |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $0 | $0 | $0 | $0 |
| Stock Repurchased | -$1M | -$2K | $0 | -$10M | -$40M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | -$2K | $0 | $2M | $0 |
| Financing Cash Flow | $22M | -$2K | $4M | -$9M | -$33M |
| Net Change in Cash | $13M | $3M | -$23M | -$14M | $1M |
| Cash End of Period | $37M | $40M | $17M | $3M | $4M |
| Free Cash Flow | -$10M | $4M | $185M | -$11M | $125M |